Internal radiotherapy techniques using radiolanthanide praseodymium-142: A review of production routes, brachytherapy, unsealed source therapy

Annals of Nuclear Medicine

Volumn 25, Issue 8, 2011, Pages 529-535

  Bakht, Mohamadreza K ^a   Sadeghi, Mahdi ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

Author keywords

Brachytherapy; Internal radiotherapy; Praseodymium 142; Radionuclide production; Unsealed source therapy

Indexed keywords

MICROSPHERE; PRASEODYMIUM; PRASEODYMIUM 142; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTERIOVENOUS MALFORMATION; BRACHYTHERAPY; CANCER RADIOTHERAPY; CYCLOTRON; DRUG DISTRIBUTION; GAMMA RADIATION; HUMAN; IRRADIATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW;

BRACHYTHERAPY; CYCLOTRONS; FEMALE; GAMMA RAYS; HUMANS; LANTHANOID SERIES ELEMENTS; MALE; MICROSPHERES; NEOPLASMS; NUCLEAR MEDICINE; PRASEODYMIUM; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOMETRY;

EID: 81855170242     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-011-0505-z     Document Type: Review

References (65)

1. A Mushtaq 2010 Reactors are indispensable for radioisotope production Ann Nucl Med 24 759 760 20976574 10.1007/s12149-010-0425-3
2. CA Hoefnagel 1998 Radionuclide cancer therapy Ann Nucl Med 12 61 70 9637275 10.1007/BF03164831 1:CAS:528:DyaK1cXks1KisLc%3D (Pubitemid 28259383)
3. R Mikolajczak JL Parus 2005 Reactor produced beta-emitting nuclides for nuclear medicine World J Nucl Med 4 184 190
4. M Sadeghi M Enferadi A Shirazi 2010 External and internal radiation therapy: past and future directions J Can Res Ther 6 239 248 10.4103/0973-1482.73324 1:CAS:528:DC%2BC3MXitlent7c%3D
5. AI Kassis SJ Adelstein 2005 Radiobiologic principles in radionuclide therapy J Nucl Med 46 4 12
6. 165Er by proton induced reactions on erbiumin comparison with other production routes Appl Radiat Isot 67 243 247 19059787 10.1016/j.apradiso.2008.10.006 1:CAS:528:DC%2BD1MXht1yrtQ%3D%3D
7. M Jackson 2000 Magnetism of rare earth IRM Quarterly 3 1 8
8. 142Pr. Open access dissertations and theses 1973. http://digitalcommons.mcmaster.ca/opendissertations/3672.
9. 142Pr glass seeds for brachytherapy Appl Radiat Isot 66 441 449 18171619 10.1016/j.apradiso.2007.11.008 1:CAS:528:DC%2BD1cXisl2jur4%3D (Pubitemid 351288534)
10. 143Pr for radionuclide therapy (RNT) applications. In: Proceedings of the 5th International Conference on Isotopes (5ICI), Brussels, Belgium, 25-29 April 2005;5ICI:103-107.
11. 142Pr]-DTPA for application in radionuclide therapy. In: Proceedings of the 5th International Conference on Isotopes (5ICI), Brussels, Belgium, 25-29 April 2005;5ICI:521-6.
12. SK Zeisler DW Becker K Weber 1999 Szilard-Chalmers reaction in praseodymium compounds J Radioanal Nucl Chem 240 637 641 10.1007/BF02349425 1:CAS:528:DyaK1MXlvVeks70%3D (Pubitemid 29232308)
13. 142Pr microspheres as a potential treatment for arteriovenous malformations Phys Med Biol 50 151 166 15715429 10.1088/0031-9155/50/1/012 (Pubitemid 40185407)
14. Lee SW. Beta dose calculation in human arteries for various brachytherapy seed types. Doctoral dissertation, Texas A&M University. http://hdl.handle.net/1969.1/42. Accessed 30 Sept 2004.
15. 142Pr glass seeds for the brachytherapy of prostate cancer. Doctoral dissertation, Texas A&M University. http://hdl.handle.net/1969.1/ 5738. Accessed 17 Sept 2007.
16. 32P intravascular brachytherapy source from Monte Carlo calculations Med Phys 28 93 103
17. 142Pr: a potential for therapeutic applications and biodistribution studies. J Radioanal Nucl Chem. 2011. doi: 10.1007/s10967-011-1033-y.
18. Mayles P, Nahum A, Rosenwald JC. Handbook of radiotherapy physics: theory and practice. London: Taylor & Francis; 2007.
19. Podgorsak EB. Radiation oncology physics: a handbook for teachers and students. Vienna: International Atomic Energy Agency IAEA; 2005.
20. B Brans L Bodei F Giammarile O Linden M Luster WG Oyen, et al. 2007 Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray" Eur J Nucl Med Mol Imaging 34 772 786 17268773 10.1007/s00259-006-0338-5 1:STN:280:DC%2BD2s3kvFSktg%3D%3D (Pubitemid 46669368)
21. A Hermanne F Tárkányi S Takács F Ditrói M Baba T Ohtshuki, et al. 2009 Excitation functions for production of medically relevant radioisotopes in deuteron irradiations of Pr and Tm targets Nucl Instr Meth B 267 727 736 10.1016/j.nimb.2008.12.017 1:CAS:528:DC%2BD1MXisl2qsL8%3D
22. RG Dale 1996 Dose-rate effects in targeted radiotherapy Phys Med Biol 41 1871 1884 8912367 10.1088/0031-9155/41/10/001 1:STN:280:DyaK2s%2FmvFaitw%3D%3D (Pubitemid 26333627)
23. RG Dale B Jones 1999 Enhanced normal tissue doses caused by tumour shrinkage during brachytherapy Br J Radiol 72 499 501 10505017 1:STN:280:DyaK1MvjsVKnsw%3D%3D (Pubitemid 29241590)
24. J Carlsson V Eriksson B Stenerlow H Lundqvist 2006 Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy Eur J Nucl Med Mol Imaging 33 1185 1195 16718515 10.1007/s00259-006-0109-3 1:CAS:528:DC%2BD28XhtVahurvO (Pubitemid 44484475)
25. DJ Brenner EJ Hall 1999 Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 43 1095 1101 10192361 10.1016/S0360-3016(98)00438-6 1:STN:280:DyaK1M3gs1Gkuw%3D%3D (Pubitemid 29144800)
26. JF Fowler RJ Chappell MA Ritter 2001 Is α/β for prostate tumours really low? Int J Radiat Oncol Biol Phys 50 1021 1031 11429230 10.1016/S0360-3016(01)01607-8 1:STN:280:DC%2BD3Mznt1Knug%3D%3D (Pubitemid 32594841)
27. DJ Brenner 2003 Hypofractionation for prostate cancer radiotherapy-what are the issues? Int J Radiat Oncol Biol Phys 57 912 914 14575821 10.1016/S0360-3016(03)01456-1 (Pubitemid 37324108)
28. AE Nahum B Movsas EM Horwitz CC Stobbe JD Chapman 2003 Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the α/β ratio Int J Radiat Oncol Biol Phys 57 391 401 12957250 10.1016/S0360-3016(03)00534-0 (Pubitemid 37040935)
29. 2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings Urology 60 634 639 12385924 10.1016/S0090-4295(02)01858-7 (Pubitemid 35246449)
30. C Parker M Milosevic A Toi J Sweet T Panzarella R Bristow, et al. 2004 Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer Int J Radiat Oncol Biol Phys 58 750 757 14967430 10.1016/S0360-3016(03)00821-6 (Pubitemid 38010336)
31. S Nag R Dobelbower G Glasgow G Gustafson N Syed B Thomadsen, et al. 2003 Intersociety standards for the performance of brachytherapy: a joint report from ABS, ACMP and ACRO Crit Rev Oncol Hematol 48 1 17 14585480 10.1016/S1040- 8428(03)00026-X (Pubitemid 37324687)
32. C Regueiro 2002 Brachytherapy: basic concepts, current clinical indications and future perspectives Rev Oncol 4 512 516
33. S Loeb RB Nadler 2006 Management of the complications of external beam radiotherapy and brachytherapy Curr Urol Rep 7 200 208 16630523 10.1007/s11934-006-0022-0 (Pubitemid 44624005)
34. S Saito H Nagata M Kosugi K Toya 2007 Brachytherapy with permanent seed implantation Int J Clin Oncol 12 395 397 18071858 10.1007/s10147-007-0710-x (Pubitemid 350243841)
35. P Broens E Van Limbergen F Penninckx 1998 Clinical and manometric effects of combined external beam irradiation and brachytherapy for anal cancer Int J Colorectal Dis 13 68 72 9638490 10.1007/s003840050137 1:STN:280: DyaK1czgt1entA%3D%3D (Pubitemid 28239677)
36. J Julow A Viola T Majo I Valálik S Sági L Mange, et al. 2004 Iodine-125 brachytherapy of brain stem tumors Strahlenther Onkol 180 449 454 15241533 10.1007/s00066-004-1228-z (Pubitemid 39207384)
37. 32P β-emitting stents Cardiovasc Radiat Med 2 143 150 11786320 10.1016/S1522-1865(01)00077-4 1:STN:280:DC%2BD387ltVKmtg%3D%3D (Pubitemid 34098722)
38. M Golombeck S Heise K Schloesser B Schuessler H Schweickert 2003 Intravascular brachytherapy with radioactive stents produced by ion implantation Nucl Instr Meth Phys Res 206 495 500 10.1016/S0168-583X(03)00806-1 1:CAS:528:DC%2BD3sXjvFajt7c%3D
39. 103Pd gamma (X-ray) source for vascular brachytherapy Cardiovasc Radiat Med 3 278 287 10.1016/S1522-1865(99)00015-3
40. 125I-brachytherapy seed for its application in the treatment of eye and prostate cancer Appl Radiat Isot 67 1421 1425 19282194 10.1016/j.apradiso. 2009.02.040 1:CAS:528:DC%2BD1MXmvVOlt7o%3D
41. 153Sm brachytherapy source Med Phys 37 5370 5375 21089772 10.1118/1.3488971
42. MCNP-A general Monte Carlo N-particle transport code, Version 5, X-5 Monte Carlo Team, Los Alamos National Laboratory; 2008.
43. E Minar B Pokrajac R Ahmadi T Maca W Seitz A Stuempflen, et al. 1998 Brachytherapy for prophylaxis of restenosis after longsegment femoropopliteal angioplasty: pilot study Radiology 208 173 179 9646810 1:STN:280: DyaK1czhtVOkug%3D%3D (Pubitemid 28323327)
44. E Minar B Pokrajac T Maca R Ahmadi C Fellner M Mittelboeck, et al. 2000 Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective, randomized study Circulation 102 2694 2699 11094034 1:STN:280:DC%2BD3M%2FmtVyntA%3D%3D
45. 192Ir HDR brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna-2 trial radiotherapy parameters and risk factor analysis Int J Radiat Oncol Biol Phys 48 923 931 11072147 10.1016/S0360-3016(00)00716-1 1:STN:280:DC%2BD3M%2FktlSntg%3D%3D
46. B Pokrajac R Poetter RM Wolfram AC Budinsky C Kirisits B Lileg, et al. 2005 Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna-3 randomised multicenter study Radiother Oncol 74 3 9 15683661 10.1016/j.radonc.2004.08.015 (Pubitemid 40430941)
47. R Waksman JR Laird CT Jurkovitz AJ Lansky F Gerrits AS Kosinski, et al. 2001 Intravascular radiation therapy following balloon angioplasty of narrowed femoro-popliteal arteries to prevent restenosis: results of the PARIS feasibility clinical trial J Vasc Interv Radiol 12 915 921 11487671 10.1016/S1051-0443(07)61569-3 1:STN:280:DC%2BD3MvktFOkuw%3D%3D (Pubitemid 32756860)
48. Davidson AS, Morgan MK. The embryologic basis for the anatomy of the cerebral vasculature related to arteriovenous malformations. J Clin Neurosci. 2011. doi: 10.1016/j.jocn.2010.12.004.
49. RL Jeffree MA Stoodley 2009 Postnatal development of arteriovenous malformations Pediatr Neurosurg 45 296 304 19690446 10.1159/000235604
50. AS Achrol R Guzman M Varga JR Adler GK Steinberg SD Chang 2009 Pathogenesis and radiobiology of brain arteriovenous malformations: implications for risk stratification in natural history and posttreatment course Neurosurg Focus 26 E9 19409010 10.3171/2009.2.FOCUS0926
51. H Kim L Pawlikowska Y Chen H Su GY Yang WL Young 2009 Brain arteriovenous malformation biology relevant to hemorrhage and implication for therapeutic development Stroke 40 S95 S97 19064791 10.1161/STROKEAHA.108.533216 1:CAS:528:DC%2BD1MXitFKjurs%3D
52. 142Pr hydroxyapatite crystals: a potential therapeutic agent for radiosynovectomy. Abstracts of SNMICON 2002 Indian J Nucl Med 17 7 8
53. M Chinol S Vallabhajosula SJ Goldsmith MJ Klein KF Deutsch LK Chinen, et al. 1993 Chemistry and biological behavior of samarium-153 and rhenium-186-labeled hydroxyapatite particles: potential radiopharmaceuticals for radiation synovectomy J Nucl Med 34 1536 1542 8394883 1:CAS:528: DyaK2cXhtVSktb0%3D (Pubitemid 23254352)
54. PR Unni PR Chaudhari M Venkatesh N Ramamoorthy MR Pillai 2002 Preparation and bioevaluation of 166Ho labelled hydroxyapatite (HA) particles for radiosynovectomy Nucl Med Biol 29 199 209 11823125 10.1016/S0969-8051(01)00303-1 1:CAS:528:DC%2BD38XovFCnug%3D%3D (Pubitemid 34127953)
55. E Deutsch JW Brodack KF Deutsch 1993 Radiation synovectomy revisited Eur J Nucl Med 20 1113 1127 8287881 10.1007/BF00173494 1:STN:280: DyaK2c7hs1Gnug%3D%3D (Pubitemid 23353806)
56. GK Gedik O Ugur B Atilla M Pekmezci M Yildirim B Seven, et al. 2006 Comparison of extraarticular leakage values of radiopharmaceuticals used for radionuclide synovectomy Ann Nucl Med 20 183 188 16715948 10.1007/BF03027428 1:CAS:528:DC%2BD28Xms1Ogu7k%3D (Pubitemid 43925961)
57. Gratz S, G6bel D, Behr TM, Herrmann A, Becker W. Correlation between radiation dose, synovial thickness, and efficacy of radiosynoviorthesis. J Rheumatol. 1999;26:1242-9. (Pubitemid 29268072)
58. G Clunie, Lui D, Cullul ICW, Edwards J, Ell PJ. 153Sm particulate hydroxyapatite particles for radiation synovectomy: Biodistribution data for chronic knee synovitis. J Nucl Med. 1995;36:51-7.
59. 166Ho labelled hydroxyapatite particles for radiosynovectomy. Book of extended synopsis, International Seminar on Therapeutic Applications of Radiopharmaceuticals. IAEA; 1999. p 148-9.
60. Liepe K, Zaknun JJ, Padhy A, Barrenechea E, Soroa V, Shrikant S et al. Radiosynovectomy using yttrium-90, phosphorus-32 or rhenium-188 radiocolloids versus corticoid instillation for rheumatoid arthritis of the knee. Ann Nucl Med. 2010. doi: 10.1007/s12149-011-0467-1.
61. CI Armpilia RG Dale IP Coles B Jones V Antipas 2003 The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants Int J Radiat Oncol Biol Phys 55 378 385 12527051 10.1016/S0360-3016(02)04208-6 1:CAS:528:DC%2BD3sXivVKgtw%3D%3D (Pubitemid 36069096)
62. Bersillon O, Blachot J. JEFF-3.11 radioactive decay data file, Compiled for the NEA Data Bank. http://www.nucleide.org/NucData.htm. Accessed Nov 2007.
63. NEA. JANIS 3.2. DVD a java-based nuclear data display program-2010. http://www.oecd-nea.org/pub/ret.cgi?div=SCI-DB#6907. Accessed Jun 2010.
64. EV Verdieck JM Miller 1967 Radiative capture and neutron emission in La139 + α and Ce142 + p Phys Rev 153 1253 1261 10.1103/PhysRev.153.1253 1:CAS:528:DyaF2sXntFWnuw%3D%3D
65. p = 15 MeV Nucl Phys A 90 253 260 10.1016/0375-9474(67)90232-1